Abvc Biopharma (ABVC) Gross Margin (2016 - 2025)
Abvc Biopharma's (ABVC) quarterly Gross Margin came in at 100.0% in Q4 2024, up 642984.0% YoY from N/an in Q1 2024, and little changed on a QoQ basis from 99.92% in Q3 2024.
Abvc Biopharma (ABVC) Gross Margin (2016 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has 9 years of Gross Margin data on file, last reported at 100.0% in Q4 2024.
- Quarterly Gross Margin rose 642984.0% year-over-year to 100.0% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 99.85% (up 19800.0% YoY) and the FY2025 annual result came in at 100.0%, up 15.0% from the prior year.
- Gross Margin was little changed at 100.0% in Q4 2024, from 99.92% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2024 to a low of 6329.84% in Q4 2023.
- A 5-year average of 303.58% and a median of 93.79% in 2020 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin sank 638478 bps — and 2024, when it soared 642984 bps.
- Tracing ABVC's Gross Margin over 5 years: stood at 96.94% in 2020, then tumbled by 89 bps to 10.31% in 2021, then soared by 433 bps to 54.94% in 2022, then plunged by 11622 bps to 6329.84% in 2023, then soared by 102 bps to 100.0% in 2024.
- The last three Gross Margin figures came in at 100.0% (Q4 2024), 99.92% (Q3 2024), and 99.84% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -108.32% |
| Sep 30, 2025 | -100.00% |
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 99.92% |
| Jun 30, 2024 | 99.84% |
| Mar 31, 2024 | 77.01% |
| Dec 31, 2023 | -6,329.84% |
| Sep 30, 2023 | -86.44% |
| Jun 30, 2023 | -1,094.65% |
| Mar 31, 2023 | 53.04% |
| Dec 31, 2022 | 54.94% |
| Sep 30, 2022 | 74.59% |
| Jun 30, 2022 | 97.33% |
| Mar 31, 2022 | 92.61% |
| Dec 31, 2021 | 10.31% |
| Sep 30, 2021 | 99.60% |
| Jun 30, 2021 | 97.95% |
| Mar 31, 2021 | 99.53% |
| Dec 31, 2020 | 96.94% |
| Sep 30, 2020 | 92.54% |